3 pediatric patients (between the ages of 6 months - 5 years) could have received their first or 2nd dose from the Dark Pink cap instead of Blue cap at their facility, essentially receiving a lower than authorized dose.; 3 pediatric patients (between the ages of 6 months - 5 years) could have received their first or 2nd dose from the Dark Pink cap instead of Blue cap at their facility, essentially receiving a lower than authorized dose.; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of UNDERDOSE (3 pediatric patients (between the ages of 6 months - 5 years) could have received their first or 2nd dose from the Dark Pink cap instead of Blue cap at their facility, essentially receiving a lower than authorized dose.), PRODUCT ADMINISTRATION ERROR (3 pediatric patients (between the ages of 6 months - 5 years) could have received their first or 2nd dose from the Dark Pink cap instead of Blue cap at their facility, essentially receiving a lower than authorized dose.) and NO ADVERSE EVENT (No adverse event) in a patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced UNDERDOSE (3 pediatric patients (between the ages of 6 months - 5 years) could have received their first or 2nd dose from the Dark Pink cap instead of Blue cap at their facility, essentially receiving a lower than authorized dose.), PRODUCT ADMINISTRATION ERROR (3 pediatric patients (between the ages of 6 months - 5 years) could have received their first or 2nd dose from the Dark Pink cap instead of Blue cap at their facility, essentially receiving a lower than authorized dose.) and NO ADVERSE EVENT (No adverse event). At the time of the report, UNDERDOSE (3 pediatric patients (between the ages of 6 months - 5 years) could have received their first or 2nd dose from the Dark Pink cap instead of Blue cap at their facility, essentially receiving a lower than authorized dose.), PRODUCT ADMINISTRATION ERROR (3 pediatric patients (between the ages of 6 months - 5 years) could have received their first or 2nd dose from the Dark Pink cap instead of Blue cap at their facility, essentially receiving a lower than authorized dose.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for UNDERDOSE (3 pediatric patients (between the ages of 6 months - 5 years) could have received their first or 2nd dose from the Dark Pink cap instead of Blue cap at their facility, essentially receiving a lower than authorized dose.) and PRODUCT ADMINISTRATION ERROR (3 pediatric patients (between the ages of 6 months - 5 years) could have received their first or 2nd dose from the Dark Pink cap instead of Blue cap at their facility, essentially receiving a lower than authorized dose.).    Patient age was reported as between 6 months to 5 years. Other patient details were not reported.  Concomitant product use was not provided by the reporter.  Suspect vaccine dosage text was reported as unknown. Lot number and dates of administration was not reported. It was reported that that they order their Moderna COVID-19 bivalent vaccine through the Department of Health. The last time they ordered the vaccine, they only received the vials with the Dark Pink cap and not the blue cap vials.  Treatment information was not provided.  This case contains information about patient 2nd out of 3 pediatric patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-736989 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-736989:Master case (Patient 1)